Physician profile
Tracy J Eicher
NPI 1578540084
$269,311.25
in general payments reported to CMS, 2019-2025
19 companies · $37K in 2025
The $37K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75K · 2020: $11K · 2021: $39K · 2022: $27K · 2023: $28K · 2024: $53K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $99K · Consulting Fee: $12K · Travel and Lodging: $3,232 · Food and Beverage: $2,499 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $99,098.50 |
| Consulting Fee | $12,439.09 |
| Travel and Lodging | $3,232.26 |
| Food and Beverage | $2,499.37 |
| Education | $166.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $100,921.21 | 2019-2025 | Ultomiris, Soliris |
| Genzyme Corporation | $55,449.23 | 2019-2023 | |
| Biogen, INC. | $48,001.52 | 2019-2023 | Tysabri, Vumerity |
| Genentech USA, INC. | $33,274.34 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $9,471.87 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $8,572.31 | 2019 | |
| Emd Serono, INC. | $5,550.22 | 2019-2025 | Mavenclad, Mavenclad |
| Merck Healthcare Kgaa | $3,187.09 | 2025 | |
| Merck Kgaa | $3,000.00 | 2025 | |
| Tg Therapeutics, INC. | $1,350.00 | 2025 | |
| Medtronic USA, INC. | $133.33 | 2019 | |
| Genentech, INC. | $95.90 | 2020 | |
| Abbvie INC. | $93.97 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $88.40 | 2019-2021 | |
| Amylyx Pharmaceuticals, INC. | $54.51 | 2023 | Relyvrio |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $33.38 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.24 | 2021 | |
| Allergan, INC. | $13.73 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Eicher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.